Skip to main content
ENDO 2026 Main banner

Pediatric and Adolescent Endocrinology

SAT-229 - Mapping the Evidence on Once-Weekly Somatrogon Versus Daily Somatropin in Prepubertal Children with Growth Hormone Deficiency: A Systematic Review

Saturday, June 13, 2026
9:30 AM - 4:30 PM CT
Location: ENDOExpo; Poster Floor
ABSTRACT
Background
Daily recombinant human growth hormone (rhGH) therapy is effective for pediatric growth hormone deficiency (GHD) but is often associated with poor adherence due to the burden of frequent injections. Once-weekly long-acting growth hormone formulations, such as somatrogon, have been developed to reduce treatment burden while preserving efficacy and safety.
Objective
To systematically evaluate the efficacy, safety and adherence of once weekly somatropin with once-daily somatropin in prepubertal children with GHD.
Methods
A systematic review was conducted in accordance with PRISMA-ScR guidelines. PubMed, ClinicalTrials.gov, and Google Scholar were systematically searched for studies, evaluating once weekly somatropin with once daily somatropin in prepubertal children with GHD. In total seven studies published between 2017 and 2025, including five randomized controlled trials, one open-label extension, and one retrospective observational study. Outcomes of interest were annualized height velocity, changes in height standard deviation score (SDS), insulin like growth factor -1 (IGF-1) levels, treatment adherence, safety and immunogenicity.
Results
Seven eligible studies involving 667 children were included comprising of five randomized controlled trials, one open-label extension, and one retrospective observational study. Annualized height velocity and changes in height standard deviation scores were comparable between somatrogon and daily somatropin across studies. Insulin-like growth factor-1 levels remained within therapeutic ranges in both groups. Somatrogon demonstrated a safety profile similar to daily rhGH, with predominantly mild to moderate adverse events. Long-term follow-up data up to five years showed sustained efficacy without clinically significant immunogenicity. Weekly dosing was consistently associated with high adherence and lower perceived treatment burden.
Conclusion
Once-weekly somatrogon demonstrates comparable efficacy and safety to daily somatropin in prepubertal children with GHD and may offer meaningful advantages by reducing injection frequency and treatment burden.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*